Drug facts

Semaglutide and pancreatitis

By David Chen·Editor·Reviewed September 2026

The symptoms the label lists¹

Section 5.2 of the Wegovy prescribing information reads as follows. The Ozempic label’s section 5.2 is the same text with its own brand name.

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY [see Adverse Reactions (6)]. After initiation of WEGOVY, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting.

The Medication Guides put it in plainer words². Wegovy’s describes “severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.” Ozempic’s is nearly identical, but it reads “with or without vomiting,” leaving nausea out.³

The pain is the symptom both labels lead with. Nausea and vomiting are described as possible companions, not requirements, and that matters on a drug where nausea alone was reported by 44% of participants on Wegovy 2.4 mg.

What the label says to do¹

To prescribers, section 5.2 says: “If pancreatitis is suspected, discontinue WEGOVY and initiate appropriate management.” Section 17, which sets out what patients should be told, says to instruct them “to discontinue WEGOVY promptly and contact their physician if pancreatitis is suspected.”

The Wegovy Medication Guide gives the patient-facing version: “Stop using WEGOVY and call your healthcare provider right away” if the pain described above occurs. The Ozempic guide gives the same instruction for Ozempic. Those are the labels’ words, reported here; this page adds nothing to them.

How often it was confirmed⁴

Section 5.2 carries no rate. The counts are in section 6.1, which reports only cases confirmed by adjudication, a formal review of each suspected case:

A patient-year is one person followed for one year, so 0.2 per 100 patient-years means about two confirmed cases for every 1,000 people treated for a year. The Wegovy label adds one further confirmed case in another trial. The Ozempic label calls its comparison group “comparator-treated”; its glycemic control trials compared Ozempic with placebo, sitagliptin, exenatide and insulin glargine.

After approval, the label lists “acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death” among reports received from use of semaglutide. Those reports are voluntary, and the label says they cannot establish a rate or a cause.

Enzyme rises without pancreatitis⁴

The labels also report pancreatic enzyme changes that were not pancreatitis. In the Wegovy weight-reduction trials, amylase rose by a mean of 15% to 16% from baseline and lipase by 39%, changes not seen on placebo. In the Ozempic trials the rises were 13% and 22%. The Wegovy label says the clinical significance of these elevations “is unknown in the absence of other signs and symptoms of pancreatitis.”

The gallbladder warning beside it¹

Section 5.3 is the next warning in the label: acute gallbladder disease. Treatment is “associated with an increased occurrence of cholelithiasis and cholecystitis,” meaning gallstones and gallbladder inflammation.

The label notes that substantial or rapid weight loss can raise the risk of gallstones on its own, but says the incidence was higher on semaglutide than placebo “even after accounting for the degree of weight loss.” The Ozempic label reports gallstones in 1.5% at 0.5 mg and 0.4% at 1 mg, and none on placebo³.

The Wegovy Medication Guide says some gallbladder problems need surgery, and lists the symptoms it wants reported: pain in the upper stomach (abdomen), yellowing of the skin or eyes (jaundice), fever, and clay-colored stools².

What the label does not say¹

The prescribing information never uses the phrase “history of pancreatitis,” and it states no rule about people who have had pancreatitis before. What it does have is a line in the Medication Guide asking patients to tell their healthcare provider before starting if they “have or have had problems with your pancreas or kidneys”². What follows from that is a prescriber’s judgment, not something the label, or this page, settles.

What none of this covers

Nothing here is medical advice. It reports the approved labels’ warnings and their own instructions, quoted and attributed, and adds none of its own. The other warnings in section 5 are on side effects, and the dehydration warning is on diarrhea. See the medical disclaimer.